In this article, we will take a detailed look at 10 stocks with at least $10 million in insider spending recently. We previously covered 11 most expensive stocks insiders are buying recently.
Since Donald Trump took office, the stock market has experienced a roller coaster ride. Nonetheless, despite concerns about tariffs, job cuts, policy changes, and geopolitical uncertainties, the broader market has risen by 1.46% year-to-date. Furthermore, equity strategists in a Reuters poll project that the broader market will finish the year 9% higher than its current level.
“Many analysts agree with this projection, arguing that the Trump administration’s policies won’t have long-term negative impacts on economic growth or inflation. Furthermore, Trump is often considered the most pro-stock market president in American history.
In addition, one factor that could support the bull market is the adoption of AI, which, according to Morgan Stanley’s Andrew Slimmon, could lead to a productivity boom similar to what happened with the Internet in the late 1990s. Slimmon also points out that investor behavior over the last few years seems similar to what it was in previous bull markets, and adhering to these patterns can be one of the most reliable strategies for driving portfolio outperformance.
When analyzing investor behavior, we chose to focus on insiders—high-level executives and directors within a company. Why focus on insiders? Because they often have valuable insights into a company’s strategy, plans, and next moves. For example, when a CEO or CFO invests their own money in company shares, it can signal strong confidence in the company’s potential.
While both insider buying and selling can be driven by various motives, it’s important to consider these actions in the context of the company’s fundamentals, industry trends, and market conditions. This is why due diligence is crucial before making any investment. However, insider trading activity, along with other relevant factors, can offer valuable insights into a company’s capabilities, helping investors make more informed decisions.
What stocks have seen at least $10 million in insider spending recently? To find out, we used Insider Monkey’s insider trading stock screener, focusing on stocks where at least one insider purchase since the beginning of the year was valued at $10 million or more. Although the total value of insider purchases during this period may be higher, only those worth $10 million or more were considered in this search. Since there were more than 10 stocks meeting this criteria, we selected the 10 stocks with insider purchases ranging from $10 million to $20 million, choosing those with the highest amounts within this range for further analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual purchase, the number of insider purchases between $10 million and $20 million since the start of the year, and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $10 million in insider spending recently.
A close-up of a trader’s hands executing a futures trade on a trading floor.
10. Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD)
Highest Individual Purchase: $10,000,000.00
Number of Purchases Worth Between $10 million and $20 million: 2
Market Capitalization: $272.22 million
The list of 10 stocks with at least $10 million in insider spending recently starts with Aardvark Therapeutics, a clinical-stage biopharmaceutical company. Its primary focus is on the development of small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Aardvark’s leading candidate is ARD-101, which is designed to target receptors expressed on enteroendocrine cells in the gut lumen, which play a key role in gut-brain signaling. The product is in Phase III clinical trials for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trials for hyperphagia associated with acquired hypothalamic obesity.
The company went public on February 12. During its initial public offering, one insider made two purchases, each valued at $10 million. The insider bought 1.25 million shares at a price of $16 per share. Currently, the stock is trading at $12.73 per share.
There is no analyst coverage available for this stock at the moment, likely because this is a new stock on the market. We can expect analyst reports as the company matures in the market.
9. Sunrise Realty Trust, Inc. (NASDAQ:SUNS)
Highest Individual Purchase: $12,000,000.00
Number of Purchases Worth Between $10 million and $20 million: 1
Market Capitalization: $155.35 million
Sunrise Realty Trust is an institutional lender that originates and funds loans to commercial real estate projects in the Southern United States. The West Palm Beach, Florida-headquartered company focuses on loans with investment rates in the mid-teens.
On January 29th, M. Leonard Tannenbaum, the executive chairman at Sunrise Realty Trust, acquired $12 million worth of the company’s shares at a price of $12 per share. With this purchase of 1 million shares, Tannenbaum increased his holdings to 2.43 million shares.
The stock is currently trading at $12.18 per share, having lost 13.49% year-to-date. At the start of the year, the stock was trading around $13 to $14 per share, so it is possible that the insider used the current drop in price to acquire more shares, demonstrating strong confidence in the company’s future.
In January, the company announced it has committed $30.8 million to a $41.0 million note-on-note bridge loan. This loan is for the full repayment of an existing senior mortgage on a mixed-use asset, featuring senior living, medical office, and retail located in an upscale suburb of Miami, Florida.
More recently, Sunrise Realty Trust confirmed it has closed on a $44 million commitment to a $74.5 million senior loan originated by the TCG Real Estate platform for the construction of Shell Plaza in New Orleans.
Two analysts have an average “Strong Buy” rating on Sunrise Realty Trust stock, with a 12-month stock price target of $15.0. This represents an increase of 23.15% from the latest price, according to Stock Analysis.
8. Metsera, Inc. (NASDAQ:MTSR)
Highest Individual Purchase: $14,219,964.00
Number of Purchases Worth Between $10 million and $20 million: 3
Market Capitalization: $2.55 billion
The eighth stock on this list of 10 stocks with at least $10 million in insider spending recently is a clinical-stage biotechnology company. Metsera focuses on developing injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. The New York City-based company is advancing its broad portfolio of therapies with the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.
On February 3rd, three insiders acquired a total of $94.22 million in Metsera shares at $18 per share during the company’s initial public offering. The company raised $257 million during its IPO, pricing shares above its targeted range. Of the five purchases, three were valued at $14.22 million each. The stock is currently trading at $24.78.
In January, the company shared promising results from a 12-week Phase 2a clinical trial of its leading candidate, MET-097i, a potential once-monthly injectable treatment for obesity. The data showed that MET-097i helped participants achieve significant weight loss, with some losing up to 20% of their body weight, and it was generally well tolerated, with only mild side effects. The company is planning additional studies in 2025.
According to data from StockAnalysis, four analysts have given Metsera stock an average ‘Strong Buy’ rating, with a price target of $47.
Metsera is also one of 10 stocks insiders spent the most money on recently.
7. TKO Group Holdings, Inc. (NYSE:TKO)
Highest Individual Purchase: $14,799,360.15
Number of Purchases Worth Between $10 million and $20 million: 3
Market Capitalization: $12.29 billion
TKO Group is a sports and entertainment giant that produces and licenses live events, TV programs, long- and short-form content, reality series, and more. It was formed by Endeavor (NYSE:EDR) as part of a merger between World Wrestling Entertainment and Zuffa, LLC, the parent company of the Ultimate Fighting Championship. The merger marked the first time WWE was no longer majority-controlled by the McMahon family, which had owned it for over 70 years.
Its content reaches over 1 billion households across approximately 210 countries and territories. Each year, the company organizes over 300 live events, attracting more than 2 million fans. TKO Group is also one of the 11 most expensive stocks insiders are buying recently.
Counting only purchases above $10 million, three investors, including the company’s CEO, acquired a total of $185.53 million in TKO Group shares at an average price of $163.80 per share. Of the total purchases, three were valued at $14.8 million each, falling within the $10 million to $20 million range. With the latest purchases, the company’s CEO, Ariel Emanuel, increased his holdings to 2.58 million TKO Group shares.
The stock is currently trading at $150.64, having gained 6% since the beginning of the year. Over the past five years, TKO Group shares have returned 84.45% to investors.
In February, the company announced that UFC and Monster Energy had signed a multiyear renewal of its long-standing partnership, under which Monster will continue as the exclusive global Official Energy Drink of UFC.
Eleven Wall Street analysts have given TKO Group stock an average “Strong Buy” rating, with a price target of $175.45 per share, data from TipRanks reveals.
6. Arcus Biosciences, Inc. (NYSE:RCUS)
Highest Individual Purchase: $14,999,996.00
Number of Purchases Worth Between $10 million and $20 million: 1
Market Capitalization: $1.15 billion
The sixth among 10 stocks with at least $10 million in recent insider spending is Arcus Biosciences, a clinical-stage, global biopharmaceutical company. Arcus is focused on developing best-in-class molecules and combination therapies for cancer patients.
Among the company’s leading candidates are Domvanalimab, an anti-TIGIT antibody currently in Phase 2 and Phase 3 clinical trials, and AB308, an investigational anti-TIGIT monoclonal antibody in a Phase 1b clinical trial studying patients with advanced solid and hematologic malignancies. TIGIT is a checkpoint protein found on immune cells in the tumor microenvironment that inhibits the immune system’s natural ability to detect and kill cancer cells.
On February 18, one investor bought nearly $15 million worth of Arcus shares at a price of $11 per share. The stock is currently trading at $10.89, reflecting a 26.86% drop year-to-date. This purchase was part of the company’s underwritten offering of 13,636,364 shares of common stock, aiming to raise approximately $150 million. The company stated it will use the net proceeds from the offering to fund ongoing research and development activities.
On the same day, Arcus announced it had retained the rights to Casdatifan, a potential best-in-class HIF-2a inhibitor. HIF-2a inhibitors are a type of medication designed to block the activity of a protein called HIF-2a (Hypoxia-Inducible Factor 2 alpha). In certain types of cancer, such as kidney cancer, HIF-2a becomes overactive and promotes the growth of tumors and the development of new blood vessels that nourish these tumors. “We are thrilled to retain ownership of casdatifan, which has the potential to address a significant unmet need for patients with an estimated $5 billion market opportunity,” stated Terry Rosen, Ph.D., chief executive officer of Arcus.
For the full year ending December 31, 2024, the company disclosed total revenues of $258 million, compared to $117 million for the prior year. Net loss amounted to $283 million, which compares to a net loss of $307 million in 2023.
Data from MarketBeat shows that 10 analysts have given Arcus stock an average ‘Buy’ rating, with a price target of $30.25. The average price target suggests an upside of 177.88%.
5. CVR Energy, Inc. (NYSE:CVI)
Highest Individual Purchase: $16,027,369.00
Number of Purchases Worth Between $10 million and $20 million: 1
Market Capitalization: $1.85 billion
CVR Energy is a diversified holding company primarily focused on renewable fuels, petroleum refining, marketing, and nitrogen fertilizer manufacturing through its subsidiary, CVR Partners, LP.
On January 8, billionaire hedge fund manager Carl Icahn purchased $16.03 million worth of CVR Energy shares at a price of $18.25 per share. With this acquisition Icahn increased his holdings to 67.57 million shares. CVR Energy is one of Icahn’s top 10 stock picks.
The stock is currently trading at $18.42 per share, as the shares slightly dropped since the beginning of the year. Over the past five years, CVR Energy shares lost 15.15%.
In 2024, the company’s revenue amounted to $7.61 billion, reflecting a 17.70% decrease compared to the previous year’s $9.25 billion. Net income attributable to CVR Energy shareholders was $7 million, or 6 cents per diluted share, compared to net income of $769 million, or $7.65 per share. The adjusted loss was 51 cents per diluted share, compared to adjusted earnings of $5.64 per diluted share.
Seven analysts have given CVR Energy an average “Strong Sell” rating, with a price target of $23.00, according to MarketBeat.
4. Beta Bionics, Inc. (NASDAQ:BBNX)
Highest Individual Purchase: $17,000,000.00
Number of Purchases Worth Between $10 million and $20 million: 1
Market Capitalization: $908.72 million
The fourth on this list of 10 stocks with at least $10 million in insider spending recently is a commercial-stage medical device company focused on developing solutions to enhance the health and quality of life of insulin-dependent people with diabetes. The company’s iLet Bionic Pancreas is an insulin delivery device for treating type 1 diabetes in adults and children six years of age and older. Beta Bionics is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing.
On January 31, one insider acquired $17 million worth of Beta Bionics shares at a price of $17 per share. This acquisition was part of the company’s $234.6 million initial public offering. The stock is currently trading at $20.97 per share.
According to seven Wall Street analysts, Beta Bionics stock is a “Strong Buy,” reveals TipRanks. The analysts have also given an average price target of $26.43, representing a 26.04% increase from the previous price.
3. Sionna Therapeutics, Inc. (NASDAQ:SION)
Highest Individual Purchase: $18,406,548.00
Number of Purchases Worth Between $10 million and $20 million: 1
Market Capitalization: $583.86 million
Sionna Therapeutics is a biopharmaceutical company focused on developing treatments for cystic fibrosis (CF). The Boston, Massachusetts-headquartered company is dedicated to developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, aiming to provide clinically meaningful benefits to CF patients. Its goal is to develop a range of medicines for individuals with CF that restore CFTR function to near-normal levels.
The company’s co-founders have more than a decade of research in this area, so Sionna is working on advancing a pipeline of small molecules engineered to correct the defects caused by the most common CF genetic mutation.
On February 10, one insider bought $18.41 million worth of Sionna shares at a price of $18 per share. The acquisition was part of the company’s upsized initial public offering, through which it raised $219.2 million. Sionna stated that it plans to use raised capital to advance its CF drug development programs. The stock is currently trading at $13.77 per share.
Given that this stock recently went public, there is limited analyst coverage and no publicly available financial reports at this time.
Sionna is also among the 10 stocks insiders are buying this year.
2. Amkor Technology Inc (NASDAQ:AMKR)
Highest Individual Purchase: $18,999,995.25
Number of Purchases Worth Between $10 million and $20 million: 5
Market Capitalization: $5.21 billion
Second on the list of stocks with at least $10 million in recent insider spending is a provider of outsourced semiconductor packaging and testing services across the U.S., Japan, Europe, and the Asia Pacific region. Its offering includes turnkey packaging and testing services, such as semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, system-level and final testing, and more.
On February 24, five insiders acquired nearly $95 million worth of Amkor shares at a price of $21.85 per share. Each individual purchase was valued at approximately $19 million. The stock is currently trading at $21.12, having lost 17.81% since the beginning of the year.
In 2024, the company reported net sales of $6.32 billion, compared to $6.50 billion in 2023. Net income attributable to Amkor was $354 million or $1.43 per diluted share, compared to net income of $360 million or $1.46 per diluted share in 2023.
Eight Wall Street analysts have given an average “Moderate Buy” rating on Amkor stock, with a price target of $29.66, according to TipRanks.
Amkor is also among 10 stocks that could skyrocket after Jensen Huang’s earnings call.
1. Sirius XM Holdings Inc. (NASDAQ:SIRI)
Highest Individual Purchase: $19,838,448.00
Number of Purchases Worth Between $10 million and $20 million: 3
Market Capitalization: $8.19 billion
The first of the 10 stocks with at least $10 million in insider spending recently is an audio entertainment company, which provides satellite radio and streaming services to more than 33 million subscribers in the U.S. Sirius XM Holdings’ offerings include a wide range of audio content, from music and sports to news and podcasts. The company was formed in 2008 through the merger of Sirius Satellite Radio and XM Satellite Radio to become SiriusXM Radio. It is also one of 12 best broadcasting stocks to buy right now.
Since the beginning of the year, one insider — Berkshire Hathaway Inc — made several investments in the stock. On January 31, it purchased 840,000 shares at an average price of $23.62 per share, making an acquisition worth $19.84 million. With its latest purchase that happened on February 2, Berkshire Hathaway Inc increased its holdings in SiriusXM Radio stock to 119.78 million shares.
The stock is now trading at $24.19, having gained 6.10% year-to-date.
Sirius XM reported fourth-quarter and full-year 2024 revenue of $2.19 billion and $8.70 billion, respectively, representing declines of 4% and 3%, respectively, compared to the same periods in 2023. Out of the total revenue, subscribers revenue amounted to $1.65 billion, which compares to $1.73 billion in the comparable quarter of the prior year. The company reported net income of $287 million for the fourth quarter and a net loss of $2.08 billion for the full year 2024, compared to net income of $228 million and $988 million in the prior year, respectively.
Ten analysts have an average “Moderate Buy” rating on SIRI stock, with a 12-month target price of $31.50, according to MarketBeat.
Overall, SIRI is first among the 10 stocks with at least $10 million in insider spending recently. While we acknowledge the potential of SIRI, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SIRI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
